Member Info for bookyjam

Blueberries, can you share the link to the 'recent statement' regarding pipeline. I wrote to BXP for more information in this regards and did not get an answer. Mkt value in Dhaka now £356m equiv. AIM Mkt value £239m. I am not seeing the gap closed and I think this is due to a lack of institutional support for the AIM GDRs

NigWit, no news from BXP. Didn't really expect a response from them but was worth a try. expecting to see the valuation gap close with a little profit taking as the sp moves up. Still holding and anticipating the next FDA RNS

NigWit, written to BXP.let see if they can provide an explanation. I am also seeking info as to what is in the pipeline seeking FDA or other regulatory approvals. Anticipating the next FDA approval though not as much as I am anticipating Halifax drill. I'll let you know if I get a response.

£353m in Dhaka, £235m on AIM. Can anyone explain? technically sp should be around 88p. is this 52% differential purely risk? am I missing something here?

NigWit, traction from here on.... Although it has risen 93% it is still not reflecting the correct valuation. The closing on the DSE was TK84 which equates to 86p. a bit of a disconnect between AIM and DSE??? I hope I am wrong of course because I will still hold for at least the medium term.

Ok, so now seeing the share structure it is becoming clearer why the sp does not reflect the high growth and earnings. none of the GDRs are held by institutional investors and the majority of the issued shares (77%) are traded on the Dhaka stock exchange. The sp has been more volatile on the DSE. Unless we begin to see some institutional support then the value will be derived mainly from the bonus and divi and not so much from the sp. With this said, it is unlikely there will be any Institutional Investor being interested in GDRs as the rights of GDR holders are limited pari passu to those of ordinary shareholders on the DSE. The company has issued less than half of the authorised share capital. Unless there is a placing of GDRs to IIs and use the proceeds to repay debt then I cannot see much traction in the sp on AIM. IMHO

NigWit, thanks for the quick insight. I bought in a small holding at 56.7 during that volatility period as a punt but now with a little more research I will defo hold and add. Let the trend be your friend and what I have seen from the 2 year chart is a rising trend.

IMHO realistically, this should be trading with a PE of at least 16 for such a high growth company. This equate to a sp of c.95p. TEVA Pharma and Israeli company who are the king of generics trades at PE of 20 and PPB 1.23. My guess is that the domiciliation is the weigh down factor. Appointment of another broker, more FDA approvals and more publicity and we should be seeing £1 very soon.

Does anyone know the GBP book value of this company vs the market cap? I am new to this BB and this stock but on first research it seems to be a high growth company with great potential. thanks

I topped up just 1k shares a couple days ago at 31.75 to avg down since i bought couple years ago at +£1. the spread when I bought was nowhere near 15%, I recall it was c.1% why the big spread?

its only an increase of 1.6m shares at pennies per share so probably worth no more than £50k. MS could have done this on behalf of a speculative client making a punt. you'll see it was done by MS wealth management arm which suggests it's not on their books.

well, as you may know, equity holders are last in line to receive anything from administration. the administrators take over and sells the asset. JSW bids for the iron ore mine, the administrators assesses whether this is the best deal and with no competing buyer the administrator accepts the bid. pays off bondholders (standard chartered), other creditors and if anything left behind after fees etc then it gets distributed to us the equity holders. WE ARE WIPED OUT UNLESS......the administrators can convince the bondholders and creditors to take a hefty discount and leave the dregs for equity holders

well! the biatch died a few weeks ago the the kennel is housing rats right now. Bets are that the wife comes home to good news then its prime sushi and the champagne flowing

both to be taken over. sounds like the JSW deal is inked just waiting for the price. I bought at 3.36p so looking for at least 15p. as for WRN I think it will be a multibagger as well

WRN and LOND. would you believe it !!!!! I'll be either bedroom lucky tonight or in the dog house :o)

I agree a Placing or dilution coming but not a major one, purely for working capital. If I'm correct, they will not incur the drill or development costs since that's with Kosmos

Based on the 25% economic interest on the low estimates, Antrim's P90 is 93mbbl. assigining a risk value of $4/bbl (the value prior to actually hitting oil), then estimated current value of $372m (£217m) which equates to a sp of 118p. This is totally IMHO and excludes many risk factors that exists the most obvious noted in the RNS in the Forward Looking Cautionary Statement. as always DYOR

Thanks for the responses. I cannot see VC getting involved in this one as R&D and jobs will not be adversely affected as was the case with AZN. I suppose the AbbVie sp and forex has a play in the sub £50 sp as well

Excuse my ignorance here but if Abbie is offering £53+ and Shire will recommend this to shareholders then why is the SP still languishing below £50? are they waiting for the formal offer to be made or is the market saying that this is not quite a done deal?